Quantcast

Posts related to ‘LLY’

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

We are now just about two weeks away from the king of biotech and pharma events in cancer treatments.  The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) ...
Read Full Story »

Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CYTR, GALE, EXEL, GNBT, GHDX, IMGN, NKTR, NLNK, PCYC, SGEN)

It is now getting close to the middle of May, and that means one thing for biotech investors.  The king of biotech and pharma events is about to take place.  ...
Read Full Story »

Amylin Seeks a Buyer (AMLN, CS, GS, BMY, SNY, LLY, AZN, MRK)

Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer ...
Read Full Story »

The Inevitable Amylin Buyout (AMLN, BMY, LLY, ALKS)

If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN).  News from Bloomberg is out that the company has rejected an ...
Read Full Story »

Diabetes Drug Approved For Europe (AMLN, LLY)

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) and Eli Lilly & Co. (NYSE: LLY) are in the news on the diabetes front.  The companies have announced that the European Commission has now ...
Read Full Story »

Dendreon Rises on Takeover Chatter (DNDN, LLY, AMGN)

Dendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As Streetinsider.com points out, the company’s new chairman presided over the ...
Read Full Story »

The 10 Largest Hedge Funds in America

By now, most investors know that the large hedge funds are run by billionaires rather than millionaires. What many investors might not know is that some hedge funds are reaching ...
Read Full Story »

24/7 Wall St. Closing Bell (XOM, NKE, POT, TSLA, AMGN, RRC, AXE, ARMH, CE, LLY, HP, LLL, MHP, MAT, PFE, VLO, VRNG, RSH, PAY, REE, FFN)

All three major indexes opened higher this morning, but the strength didn’t last as the Chicago PMI number failed to meet expectations and came in lower even than last month’s ...
Read Full Story »

Media Digest (11/9/2011) Reuters, WSJ, NYTimes, FT

Greece will announce its new government today. (Reuters) Inflation in China drops in October. (Reuters) Olympus investment losses may have gone above $1 billion. (Reuters) Silvio Berlusconi leaves as prime ...
Read Full Story »

Lilly’s Drugs Closer to Edge of Patent Cliff (LLY, PFE, JNJ, BMY, SNY, MRK)

Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better than analysts expected, but worries persist that the company will ...
Read Full Story »

Lipitor OTC: What Next? (PFE, MRK, AZN, SNY, BMY, LLY, JNJ, AMGN)

Once patent protection expires on a prescription drug, the drug's maker can take a serious beating in revenue and profitability. One way to make up for the loss is to ...
Read Full Story »

Pharma Earnings Winner: Pfizer Versus Merck (MRK, PFE, LLY)

Merck & Co. Inc. (NYSE: MRK) released second-quarter results last Friday and Pfizer Inc. (NYSE: PFE) reported this morning.  The results of both drug behemoths are largely in line with ...
Read Full Story »

Media Digest (7/20/2011) Reuters, WSJ, NYT, FT, Bloomberg

Apple Inc (NASDAQ: AAPL) reported better than expected earnings and its shares soared (Reuters) Yahoo!'s (NASDAQ: YHOO) revenue fell (Reuters) A settlement of the debate over the U.S. debt pushed ...
Read Full Story »

The Weeks Stock Market Winners: Eli Lilly, Goodyear, General Mills, and More

The number of stocks that made substantial gains for the week was limited. The great exception to that rule was Petrohawk Energy Corporation Co (NYSE: HK) which jumped 62.5% on ...
Read Full Story »

Beyond the Pharma Patent Cliff, Dividends Galore (LLY, BMY, MRK, PFE, ABT)

Many drug companies face a what is called a patent cliff ahead, where the Big Pharma players will have key drugs go off-patent and there will be new generic competition.  ...
Read Full Story »